A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Registration Number
- NCT06211764
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 250
- Histologically confirmed diagnosis by local pathology (within 90 days of documented informed consent) of recurrent, papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) [defined as high-grade Ta or any T1, no carcinoma in situ (CIS)]
- Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial (transitional cell histology) predominance. However, neuroendocrine, and small cell variants will be excluded
- Participants must be ineligible for or have elected not to undergo Radical Cystectomy (RC)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2
- Presence of CIS at any point from time of diagnosis of papillary-only HR-NMIBC recurrence to randomization. Additionally, presence or history of histologically confirmed, muscle-invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, T2, T3, T4, N+, and/or M+)
- Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200. Participants with tumors involving the prostatic urethra in men will be excluded
- A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (>4000 mL)
- Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
- Previous treatment with TAR-200
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group B: Mitomycin C (MMC) or Gemcitabine Mitomycin C Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase. Group B: Mitomycin C (MMC) or Gemcitabine Gemcitabine Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase. Group A: TAR-200 TAR-200 Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase.
- Primary Outcome Measures
Name Time Method Disease-free Survival (DFS) Up to 6 years 7 months DFS will be measured as the time from randomization to the time of the first recurrence of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) \[high grade (HG) Ta, any T1 or carcinoma in situ (CIS)\], progression, or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Recurrence-Free Survival (RFS) Up to 6 years 7 months RFS will be measured as the time from randomization to the time of the first recurrence of HR-NMIBC (HG Ta, any T1 or CIS), or death due to any cause, whichever occurs first.
Time to Next Intervention (TTNI) Up to 6 years 7 months TTNI will be measured as the time from randomization to the time of next intervention (localized or systemic) for the treatment of bladder cancer.
Time to Disease Worsening (TTDW) Up to 6 years 7 months TTDW is measured as the time from randomization to cystectomy, systemic therapy, or radiation therapy (treatments of disease worsening).
Time to Progression (TTP) Up to 6 years 7 months TTP will be measured as the time from randomization to the time of first documented evidence of disease progression (that is, progression to muscle-invasive bladder cancer \[MIBC\] \[T greater than or equal to {\>=} 2\], lymph node \[N+\], or distant disease \[M+\]), or death due to disease progression, whichever occurs first.
Overall Survival (OS) Up to 6 years 7 months OS is defined as the time from randomization to death, due to any cause.
DFS Rate at 12 and 24 Months At 12 and 24 months DFS rate that is percentage of participants with DFS at 12 and 24 months will be reported.
Number of Participants with Adverse Events (AEs) According to Common Terminology Criteria for Adverse Events (CTCAE) Up to 6 years 7 months Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.
Number of Participants With Change from Baseline in Laboratory Abnormalities Up to 6 years 7 months Number of participants with change from baseline in laboratory abnormalities (including hematology, clinical chemistry and routine urinalysis) will be reported.
Number of Participants With Change from Baseline in Vital Signs Abnormalities Up to 6 years 7 months Number of participants with change from baseline in vital signs including temperature, pulse/heart rate, respiratory rate, and blood pressure (systolic and diastolic) (supine) will be reported.
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ) - C30 Scores Up to 5 years EORTC QLQ-C30 is a 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much).
Change from Baseline in EORTC QLQ- Non-Muscle-Invasive Bladder Cancer (NMIBC) 24 Scores Up to 5 years EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with NMIBC. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales (urinary symptoms, malaise, future worries, bloating and flatulence, sexual function and male sexual problems) and 5 single items (intravesical treatment issues, sexual intimacy, worries about risk of contaminating partner, sexual enjoyment, and female sexual problems). Ratings for each item range from 1 (not at all) to 4 (very much).
Proportion of Participants With Meaningful Change in EORTC QLQ-C30 and EORTC QLQ-NMIBC24 Scores Up to 5 years Proportion of participants with meaningful change in EORTC QLQ-C30 and EORTC QLQ-NMIBC24 scores will be reported.
Trial Locations
- Locations (122)
Universita Campus Bio-Medico di Roma
🇮🇹Roma, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Roma, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Hosp.Univ.Parc Tauli
🇪🇸Sabadell, Spain
PO Molinette Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino
🇮🇹Torino, Italy
Funabashi Munitiple Medical Center
🇯🇵Funabashi shi, Japan
Hakodate Goryoukaku Hospital
🇯🇵Hakodate, Japan
Hosp Virgen de La Victoria
🇪🇸Málaga, Spain
University of California Irvine Medical Center
🇺🇸Orange, California, United States
Arkansas Urology
🇺🇸Little Rock, Arkansas, United States
Genesis Research LLC
🇺🇸Torrance, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Istituto Dei Tumori Di Milano
🇮🇹Milano, Italy
University of California San Francisco
🇺🇸San Francisco, California, United States
Colorado Clinical Research
🇺🇸Lakewood, Colorado, United States
Florida Urology Partners
🇺🇸Riverview, Florida, United States
UroPartners
🇺🇸Chicago Ridge, Illinois, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Urology of Indiana
🇺🇸Carmel, Indiana, United States
First Urology, PSC
🇺🇸Jeffersonville, Indiana, United States
Wichita Urology Group
🇺🇸Wichita, Kansas, United States
Comprehensive Urology
🇺🇸Royal Oak, Michigan, United States
Specialty Clinical Research of St Louis
🇺🇸Saint Louis, Missouri, United States
Associated Medical Professionals
🇺🇸Syracuse, New York, United States
The Urology Group
🇺🇸Cincinnati, Ohio, United States
Central Ohio Urology Group
🇺🇸Gahanna, Ohio, United States
Centers for Advanced Urology LLC d b a MidLantic Urology
🇺🇸Bala-Cynwyd, Pennsylvania, United States
Ralph H. Johnson Veterans Affairs Medical Center
🇺🇸Charleston, South Carolina, United States
Carolina Urologic Research Center
🇺🇸Myrtle Beach, South Carolina, United States
Low Country Urology Clinics
🇺🇸North Charleston, South Carolina, United States
Urology Associates
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Urology Austin
🇺🇸Austin, Texas, United States
Urology Clinics of North Texas
🇺🇸Dallas, Texas, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Houston Metro Urology
🇺🇸Houston, Texas, United States
Spokane Urology
🇺🇸Spokane, Washington, United States
Clinica Santa Isabel
🇦🇷Buenos Aires, Argentina
Investigaciones Clinico Moleculares (ICM)
🇦🇷Caba, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Cordoba, Argentina
Centro Urologico Profesor Bengio
🇦🇷Cordoba, Argentina
Hospital Privado de la Comunidad
🇦🇷Mar del Plata, Argentina
AZ Sint-Jan
🇧🇪Brugge, Belgium
Cliniques Universitaires Saint Luc
🇧🇪Bruxelles, Belgium
Ziekenhuis Oost-Limburg
🇧🇪Genk, Belgium
Algemeen ziekenhuis Maria Middelares
🇧🇪Gent, Belgium
Algemeen Ziekenhuis Delta
🇧🇪Roeselare, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
NAIC Nair Antunes Instituto do Cancer
🇧🇷Bauru, Brazil
Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
🇧🇷Campinas, Brazil
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital da Bahia
🇧🇷Salvador, Brazil
Real e Benemérita Associação Portuguesa de Beneficência
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
🇧🇷São Paulo, Brazil
Peking University First Hospital
🇨🇳Beijing, China
West China School of Medicine/West China Hospital, Sichuan University
🇨🇳Cheng Du Shi, China
Chongqing Cancer Hospital
🇨🇳Chong Qing, China
Sun Yat Sen University Cancer Center
🇨🇳Guang Zhou Shi, China
Shengjing Hospital Of China Medical University
🇨🇳Shen Yang Shi, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
The Second Hospital Of Tianjin Medical University
🇨🇳Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, China
Tongji Medical College of Huazhong University Science Technology of Medicine Health Management
🇨🇳Wuhan, China
Xi an Jiaotong University Hospital
🇨🇳XI An Shi, China
Hopital Claude Huriez
🇫🇷Lille, France
Polyclinique de Limoges - Francois Chenieux
🇫🇷Limoges, France
Institut Paoli Calmettes
🇫🇷Marseille, France
APHP - Hopital Bichat - Claude Bernard
🇫🇷Paris, France
Clinique de la Croix du Sud
🇫🇷Quint-Fonsegrives, France
Chu Rennes Hopital Pontchaillou
🇫🇷Rennes, France
Hopital Foch
🇫🇷Suresnes, France
Universitaetsklinikum Halle Saale
🇩🇪Halle (Saale), Germany
Universitaetsklinikum Koeln
🇩🇪Köln, Germany
Klinikum Leverkusen gGmbH
🇩🇪Leverkusen, Germany
Universitatsklinikum Schleswig Holstein Campus Lubeck
🇩🇪Lubeck, Germany
Urologie Neandertal Praxis Mettmann
🇩🇪Mettmann, Germany
Klinikum der Universitaet Muenchen
🇩🇪Munchen, Germany
Ospedale San Donato
🇮🇹Arezzo, Italy
Ospedale Provinciale di Macerata
🇮🇹Macerata, Italy
San Raffaele Hospital
🇮🇹Milano, Italy
Hyogo Prefectural Amagasaki General Medical Center
🇯🇵Hyogo, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
National Hospital Organization Okayama Medical Center
🇯🇵Okayama, Japan
Toho University Sakura Medical Center
🇯🇵Sakura, Japan
Toranomon Hospital
🇯🇵Tokyo, Japan
Yokohama City University Medical Center
🇯🇵Yokohama, Japan
Chungbuk National University Hospital
🇰🇷Chungcheongbuk Do, Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan-si, Korea, Republic of
Uniwersytecki Szpital Kliniczny w Bialymstoku
🇵🇱Bialystok, Poland
IN VIVO Sp. z o.o
🇵🇱Bydgoszcz, Poland
Szpital Uniwersytecki w Krakowie
🇵🇱Krakow, Poland
Uniwersytecki Szpital Kliniczny nr 4
🇵🇱Lublin, Poland
Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
🇵🇱Przemysl, Poland
Szpital Wojewodzki im Sw Lukasza SP ZOZ
🇵🇱Tarnow, Poland
MICS Centrum Medyczne Torun
🇵🇱Torun, Poland
Mazowiecki Szpital Onkologiczny
🇵🇱Wieliszew, Poland
Dolnoslaskie Centrum Onkologii
🇵🇱Wroclaw, Poland
Centrul Medical Unirea SRL
🇷🇴Brasov, Romania
Ponderas Academic Hospital
🇷🇴Bucuresti, Romania
Institutul Oncologic Ion Chiricuta
🇷🇴Cluj-Napoca, Romania
Regina Maria
🇷🇴Cluj-Napoca, Romania
Spitalul Clinic Judetean de Urgenta Pius Brinzeu
🇷🇴Timisoara, Romania
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Fund. Puigvert
🇪🇸Barcelona, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Hosp. Clinico Univ. de Valencia
🇪🇸Valencia, Spain
St Bartholomews Hospital
🇬🇧London, United Kingdom
Salford Royal Hospital
🇬🇧Salford, United Kingdom
Southampton University Hospital
🇬🇧Southampton, United Kingdom
Lister Hospital
🇬🇧Stevenage, United Kingdom